User login
Interferon beta and glatiramer acetate continue to be potent, cost-effective disease modifying therapies (DMTs) for multiple sclerosis patients after 6 years, reported Dr. Jacqueline Palace of Oxford (England) University.
In a clinical cohort study of 4,137 patients with relapsing MS, both Markov and multilevel statistical models showed slower progression than predicted, with a reduction of 24.2% and 40% in Expanded Disability Status Scale (EDSS) progression, respectively. Measures of cost effectiveness showed a better utility progression ratio than the expected 62% target (Markov model: 58.5%, 95% CI 54.2-62.8; multilevel model: 57.1%, 95% CI 53.0-61.2).
The findings support a “predicted long-term effect of multiple sclerosis DMTs in patients with relapsing-onset disease, consistent with their UK cost-effectiveness at an aggregate level,” Dr. Palace and her colleagues said in the report.Read the full paper online in the Lancet.
Interferon beta and glatiramer acetate continue to be potent, cost-effective disease modifying therapies (DMTs) for multiple sclerosis patients after 6 years, reported Dr. Jacqueline Palace of Oxford (England) University.
In a clinical cohort study of 4,137 patients with relapsing MS, both Markov and multilevel statistical models showed slower progression than predicted, with a reduction of 24.2% and 40% in Expanded Disability Status Scale (EDSS) progression, respectively. Measures of cost effectiveness showed a better utility progression ratio than the expected 62% target (Markov model: 58.5%, 95% CI 54.2-62.8; multilevel model: 57.1%, 95% CI 53.0-61.2).
The findings support a “predicted long-term effect of multiple sclerosis DMTs in patients with relapsing-onset disease, consistent with their UK cost-effectiveness at an aggregate level,” Dr. Palace and her colleagues said in the report.Read the full paper online in the Lancet.
Interferon beta and glatiramer acetate continue to be potent, cost-effective disease modifying therapies (DMTs) for multiple sclerosis patients after 6 years, reported Dr. Jacqueline Palace of Oxford (England) University.
In a clinical cohort study of 4,137 patients with relapsing MS, both Markov and multilevel statistical models showed slower progression than predicted, with a reduction of 24.2% and 40% in Expanded Disability Status Scale (EDSS) progression, respectively. Measures of cost effectiveness showed a better utility progression ratio than the expected 62% target (Markov model: 58.5%, 95% CI 54.2-62.8; multilevel model: 57.1%, 95% CI 53.0-61.2).
The findings support a “predicted long-term effect of multiple sclerosis DMTs in patients with relapsing-onset disease, consistent with their UK cost-effectiveness at an aggregate level,” Dr. Palace and her colleagues said in the report.Read the full paper online in the Lancet.